<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12384">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02945722</url>
  </required_header>
  <id_info>
    <org_study_id>1608170</org_study_id>
    <secondary_id>2016-004381-25</secondary_id>
    <nct_id>NCT02945722</nct_id>
  </id_info>
  <brief_title>Study of the Impact of a Targeted Decolonization of S. Aureus Persistent Carriers</brief_title>
  <acronym>CIBERSTAPH</acronym>
  <official_title>Study of the Impact of a Targeted Decolonization of S. Aureus Persistent Carriers on the Occurrence of S. Aureus Infections in Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      S. aureus nasal carriage is a well-known risk factor for S. aureus infections in
      hemodialysis (HD) patients. Strains of carriage and infections are the same in &gt;80% of cases
      We recently shown that persistent carriers of S. aureus, not intermittent ones are at
      increased risk of staphylococcal infections in HD. Thanks to a new algorithm developped
      based on one nasal sample the determination of carriage status (persistent, intermittent or
      non-carriers) among patients is easy. Mupirocin use in HD have been shown to reduce
      significantly S. aureus infections however, multiples schedules of decolonization have been
      proposed to all S. aureus carriers. To date, there is no national guideline for
      decolonization of S. aureus in HD. We showed that only 50% of HD centers in France propose
      screening and decolonization of S. aureus carriers. The aim of the study is therefore to
      evaluate the impact of a targeted decolonization of S. aureus persistent carriers using
      mupirocin nasal ointment and chlorhexidine baths during 5 days on the occurrence of S.
      aureus infections in HD patients compared to the absence of decolonization using a
      randomized open study methodology.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hemodialysis patients will be randomized in 2 arms: one arm where persistent carriers will
      be decolonized. Decolonization schedule associate the use of mupirocin nasal ointment 3
      times a day and chlorhexidine bath once a day for 5 days. Screening of persistent carriers
      in this arm will be done every 3 months and a new decolonization will be proposed to
      patients found (again) persistent carriers. Determination of carriage status will be done
      using one nasal swab by following the algorithm previously described. Bacterial load will be
      determined by a quantitative S. aureus PCR (Polymerase Chain Reaction) : persistent carriers
      are the patient with a bacterial load &gt; 103 CFU/mL (Colony Forming Unit) .

      The other arm is HD patients in which decolonization is not performed including impersistent
      carriers.

      All infections that occurred in enrolled patients will be counted in both groups
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2017</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>S. aureus infection</measure>
    <time_frame>12 months</time_frame>
    <description>Number of S. Aureus define by Centers for Disease Control</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>endogenous S. aureus infections</measure>
    <time_frame>12 months</time_frame>
    <description>same strain of carriage and infection</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">850</enrollment>
  <condition>Hemodialysis Patients</condition>
  <arm_group>
    <arm_group_label>Decolonization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>persistent carriers will be decolonized. Decolonization schedule associate the use of mupirocin nasal ointment 3 times a day and chlorhexidine bath once a day for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No decolonization</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>HD patients in which decolonization is not performed including impersistent carriers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decolonization</intervention_name>
    <description>Decolonization schedule associate the use of mupirocin nasal ointment 3 times a day and chlorhexidine bath once a day for 5 days. Screening of persistent carriers will be done every 3 months</description>
    <arm_group_label>Decolonization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No decolonization</intervention_name>
    <description>Screening of persistent carriers in this arm will be done every 3 months</description>
    <arm_group_label>No decolonization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (age ≥ 18 years-old)

          -  Patient under chronic hemodialysis

          -  Patent that accepted to participate in the study with a written consent form signed

        Exclusion Criteria:

          -  Patients under peritoneal dialysis

          -  Patients with an active infection at the time of inclusion

          -  Patients previously treated by mupirocin and chlorhexidine for decolonization purpose

          -  Patients that received antimicrobials active on S. aureus during the month before the
             inclusion

          -  Patients with allergy to mupirocin or chlorhexidine

          -  Patients treated by hemodialysis transiently (non-terminal kidney failure)

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabeth Botelho-Nevers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SAINT-ETIENNE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elisabeth Botelho-Nevers, MD</last_name>
    <email>elisabeth.botelho-nevers@chu-st-etienne.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ch Annonay</name>
      <address>
        <city>Annonay</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch Cannes</name>
      <address>
        <city>Cannes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AuraSanté</name>
      <address>
        <city>Cebazat</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Clermont-Ferrand</name>
      <address>
        <city>Clermont-ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AGDUC</name>
      <address>
        <city>La Tronche</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aural</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HEH</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Roanne</name>
      <address>
        <city>Roanne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARTIC42</name>
      <address>
        <city>Saint Etienne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Saint-Etienne</name>
      <address>
        <city>Saint-etienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Elisabeth BOTHELO-NEVERS, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NephroCare</name>
      <address>
        <city>Sainte-foy-les-Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 26, 2016</lastchanged_date>
  <firstreceived_date>October 25, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemodialysis</keyword>
  <keyword>S. Aureus</keyword>
  <keyword>Decolonization</keyword>
  <keyword>Persistent carriage</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
